Where I see patients (2)
Selected research
-
Early Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy Trials.
Diabetes care
-
A phase 2 randomized trial with autologous polyclonal expanded regulatory T cells in children with new-onset type 1 diabetes.
Science translational medicine
-
The Role of Imatinib in Pediatric Type 1 Diabetes.
JCEM case reports
Clinical trials
STOP-T1D Low-Dose (ATG)
The primary outcome is the elapsed time from random treatment assignment to the development of diabetes or time of last contact among those randomized
Recruiting
More about this studyRituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes
The primary objective is to test whether the C-peptide response to a 2-hour mixed meal tolerance test, will be improved in participants with new onset T1D who are treated with Abatacept after Rituximab compared to those participan...
Recruiting
More about this studyJanus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1...
The primary outcome of interest is the area under the stimulated C-peptide curve over the 2-hour mixed meal glucose tolerance test conducted at the 12-month visit (Y_AUC) over the 2-hour mixed meal glucose tolerance test conducted...
Recruiting
More about this studyType 1 Diabetes Extension Study
Evaluation of changes in beta cell function over time will be measured by mixed-meal tolerance test (MMTT) -Stimulated mean C-Peptide area under the curve (AUC). C-peptide is released by the pancreas into the bloodstream in equal...
Recruiting
More about this studyContact me
Staff superheroes